FDA Denies Allergan Petition for Higher Bar for Restasis Copies

Drug Industry Daily
A A
The FDA denied a request from Allergan to reject any ANDAs referencing Restasis unless the applicant proves bioequivalence through clinical endpoints.

To View This Article:

Login

Subscribe To Drug Industry Daily